These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30268481)

  • 41. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
    Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
    Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Wei M; Ye Q; Wang X; Wang M; Hu Y; Yang Y; Yang J; Cai J
    Medicine (Baltimore); 2018 May; 97(19):e0632. PubMed ID: 29742701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application and limitation of radiomics approach to prognostic prediction for lung stereotactic body radiotherapy using breath-hold CT images with random survival forest: A multi-institutional study.
    Kakino R; Nakamura M; Mitsuyoshi T; Shintani T; Kokubo M; Negoro Y; Fushiki M; Ogura M; Itasaka S; Yamauchi C; Otsu S; Sakamoto T; Sakamoto M; Araki N; Hirashima H; Adachi T; Matsuo Y; Mizowaki T
    Med Phys; 2020 Sep; 47(9):4634-4643. PubMed ID: 32645224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
    Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
    Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.
    Zhu X; Dong D; Chen Z; Fang M; Zhang L; Song J; Yu D; Zang Y; Liu Z; Shi J; Tian J
    Eur Radiol; 2018 Jul; 28(7):2772-2778. PubMed ID: 29450713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic factors in patients with stage III and IV non-small cell lung cancer].
    Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy.
    Li Q; Kim J; Balagurunathan Y; Qi J; Liu Y; Latifi K; Moros EG; Schabath MB; Ye Z; Gillies RJ; Dilling TJ
    Radiat Oncol; 2017 Sep; 12(1):158. PubMed ID: 28946909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lung cancer chemotherapy. Response-survival relationship depends on the method of chest tumor response evaluation.
    Pujol JL; Parrat E; Lehmann M; Gautier V; Daurès JP; Michel FB; Godard P
    Am J Respir Crit Care Med; 1996 Jan; 153(1):243-9. PubMed ID: 8542123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors.
    Kim H; Park CM; Keam B; Park SJ; Kim M; Kim TM; Kim DW; Heo DS; Goo JM
    PLoS One; 2017; 12(11):e0187500. PubMed ID: 29099855
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
    Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
    Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC.
    Dercle L; Fronheiser M; Rizvi NA; Hellmann MD; Maier S; Hayes W; Yang H; Guo P; Fojo T; Schwartz LH; Zhao B; Leung DK
    J Thorac Oncol; 2023 May; 18(5):587-598. PubMed ID: 36646209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis.
    Sun W; Jiang M; Dang J; Chang P; Yin FF
    Radiat Oncol; 2018 Oct; 13(1):197. PubMed ID: 30290849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
    Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
    Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC.
    Coroller TP; Agrawal V; Huynh E; Narayan V; Lee SW; Mak RH; Aerts HJWL
    J Thorac Oncol; 2017 Mar; 12(3):467-476. PubMed ID: 27903462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiomics Signature: A Biomarker for the Preoperative Distant Metastatic Prediction of Stage I Nonsmall Cell Lung Cancer.
    Fan L; Fang M; Tu W; Zhang D; Wang Y; Zhou X; Xia Y; Li Z; Liu S
    Acad Radiol; 2019 Sep; 26(9):1253-1261. PubMed ID: 30527455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH; Lin LZ; Zhou YQ; Luo RC; Liu KF; Jia YJ; Chen JY; Niu XW; Su BR; Lu J; Wang ST
    Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung cancer?
    Tankyevych O; Tixier F; Antonorsi N; Filali Razzouki A; Mondon R; Pinto-Leite T; Visvikis D; Hatt M; Cheze Le Rest C
    Methods; 2021 Apr; 188():73-83. PubMed ID: 33197567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy.
    Li Q; Kim J; Balagurunathan Y; Liu Y; Latifi K; Stringfield O; Garcia A; Moros EG; Dilling TJ; Schabath MB; Ye Z; Gillies RJ
    Med Phys; 2017 Aug; 44(8):4341-4349. PubMed ID: 28464316
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Distinguishing granulomas from adenocarcinomas by integrating stable and discriminating radiomic features on non-contrast computed tomography scans.
    Khorrami M; Bera K; Thawani R; Rajiah P; Gupta A; Fu P; Linden P; Pennell N; Jacono F; Gilkeson RC; Velcheti V; Madabhushi A
    Eur J Cancer; 2021 May; 148():146-158. PubMed ID: 33743483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.